LIquid Biopsy to prEdict Responses To First-line immunotherapY in Metastatic Non-small Cell LUNG Cancer. LIBERTY LUNG

ConditionMetastatic Lung Cancer

Trial statusRecruiting

Trial phaseNot applicable

Trial typeInterventional

Biological sexAll

Age18+

SponsorInstitut Curie

About this trial

Patient with histologically proven NSCLC in a metastatic stage, treatment naïve and eligible for first-line treatment with immune checkpoint inhibitor. Combination with chemotherapy is possible. Presence of a mutation after NGS analysis is required for ctDNA follow-up.

Eligibility criteria

Qualifiers

Histologically-proven NSCLC.

Age ≥ 18 years.

Advanced or metastatic stage IV.

Treatment-naïve patient.

Disqualifiers

No social security affiliation.

Person under legal protection.

Pregnant and breastfeeding women.

Trial design

Treatments tested in this trial

assessment of the predictive value of ctDNA level of the prominent mutant allele variation between baseline and week 6, on response to treatment according to RECIST 1.1 criteria.

Treatment groups

300 Participants

are divided into 1 treatment group

Sponsors and collaborators

Institut Curie

Lead sponsor

Source ClinicalTrials.gov